Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  SBI Holdings Inc    8473   JP3436120004

News SummaryMost relevantAll newsSector news 

SBI Holdings, Inc. : Basic Agreement Reached with the Bahrain Development Bank for Promoting 5-ALA Business in Bahrain

share with twitter share with LinkedIn share with facebook
share via e-mail
03/21/2013 | 07:53am CEST

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in

reliance upon the whole or any part of the contents of this announcement.


(Incorporated in Japan with limited liability)


This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The
Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board SBI Holdings, Inc. Yoshitaka Kitao Representative Director,

President & Chief Executive Officer

Japan, 21 March 2013

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Tomoya Asakura, Mr Shumpei Morita, Mr Noriaki Maruyama and Mr Peilung Li, the non-executive Directors are Mr Hiroyoshi Kido, Mr Noriyoshi Kimura, Mr Hiroshi Tasaka and Mr Takashi Okita and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Akihiro Tamaki and Mr Masanao Marumono.

21 March 2013
SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488)

Basic Agreement Reached with the Bahrain Development Bank for Promoting 5-ALA Business in Bahrain

We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo;
Representative Director and CEO: Yoshitaka Kitao; "SBI Pharmaceuticals"), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached a basic agreement to cooperate in promoting the 5-ALA business in Bahrain
with the Bahrain Development Bank (Location: Manama, Bahrain; Representative: Shaikh Mohammed Bin Essa Bin Mohammed Al Khalifa) that is engaged in providing business support to small- and medium-sized companies under the umbrella of the Bahrain government.
The Bahrain Development Bank is a governmental financial institution in Bahrain and was established in 1992 for promoting the business projects of small- and medium-sized companies in Bahrain.
SBI Pharmaceuticals is currently working with various partners, including local universities, research institutions and private companies, as it prepares for the research and development of pharmaceuticals which use 5-ALA and for manufacturing and selling 5-ALA related products; and it will promote the research and development as well as the manufacturing and sales of pharmaceuticals which use 5-ALA, while relying on local legal and financial advice and support from the Bahrain Development Bank. SBI Pharmaceuticals is hoping to further accelerate the expansion of its 5-ALA business in Bahrain, with the cooperation of the Bahrain Development Bank obtained by this basic agreement.
SBI Pharmaceuticals will continue to cooperate closely with the Bahrain government in promoting the business, while pursuing various possibilities of 5-ALA in order to contribute to the health of as many people in the
world as possible, and will make every effort to work on research and development as well as on spreading
5-ALA related products with partners both inside and outside Japan.

(*1) 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

**************************************************************************************** For further information, please contact:
SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126
SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SBI HOLDINGS INC
10/21 SBI : Biotech’s Licensed Product, an Anti-ILT7 Antibody (MEDI7734*) Has Ac..
10/20 SBI : BITS Launches New ALPHA8 Trader Workstation entry
10/18 SBI : Interim Results Announcement for the Six Months Ended September 30, 2016 o..
10/10 Ripple Labs Raises USD55 Million in Series B Funding Round
09/28 SBI HOLDINGS INC : ex-dividend day for interim dividend
09/23 SBI : Establishment of a FinTech Joint Venture Company Together with Carret Priv..
09/23 SBI : Result and Completion of Share Repurchase (Repurchase of Company Shares Pu..
09/20 SBI : Navig8 Chemical Tankers and SBI finalise sale and leaseback deal for two t..
08/12 SBI : Japan Industrial Solutions Acquires NARUMIYA INTERNATIONAL from SBI Holdin..
07/14 SBI : Indegy Raises USD12 Million in Series A Round of Financing
More news
Sector news : Diversified Investment Services
10/21 HURRICANE ENERGY : Macquarie closes its London oil and gas investment desk
10/20 EXCLUSIVE : Swiss lobby U.S. ahead of UBS, Credit Suisse RMBS settlements
10/20DJCREDIT SUISSE : Revamp Takes Shape, but Doubts Remain
10/20DJJPMORGAN CHASE : J.P. Morgan in Talks to Sell Stake in China Investment-Banking ..
10/19DJNATIXIS : China Growth Holds Steady With Help From Stimulus
More sector news : Diversified Investment Services
Financials ( JPY)
Sales 2017 260 000 M
EBIT 2017 -
Net income 2017 26 125 M
Debt 2017 -
Yield 2017 2,54%
P/E ratio 2017 9,76
P/E ratio 2018 9,23
Capi. / Sales 2017 1,02x
Capi. / Sales 2018 0,99x
Capitalization 265 207 M
More Financials
Duration : Period :
SBI Holdings Inc Technical Analysis Chart | 8473 | JP3436120004 | 4-Traders
Full-screen chart
Technical analysis trends SBI HOLDINGS INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 1 270  JPY
Spread / Average Target 7,5%
Consensus details
EPS Revisions
More Estimates Revisions
Yoshitaka Kitao President & Representative Director
Tomoya Asakura Director & Senior Managing Executive Officer
Shumpei Morita Director & Managing Executive Officer
Kiyoshi Nagano Independent Outside Director
Keiji Watanabe Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CITIC LTD-13.90%43 206
NATIXIS-11.96%15 680
More Results